# MAIA Biotechnology (MAIA) — News

MAIA · AMEX · Stock

Canonical page: https://www.lighthorse.io/tickers/maia/news

## Recent headlines

- [Micro Systemation: MSAB (Micro Systemation AB, publ) provides preliminary update for the third quarter of 2026 – Operating profit (EBIT) exceeds expectations](https://www.ainvest.com/news/micro-systemation-msab-micro-systemation-ab-publ-preliminary-update-quarter-2026-operating-profit-ebit-exceeds-expectations-2610) — AInvest Wire, Oct 14, 2026
- [Epiroc AB: Barclays raises target price to SEK 285 from SEK 280](https://www.ainvest.com/news/epiroc-ab-barclays-raises-target-price-sek-285-sek-280-2610) — AInvest Wire, Oct 14, 2026
  Barclays has raised its target price for Epiroc AB (EPI.A) to SEK 285 from SEK 280, reflecting the firm’s confidence in the company’s operational performance and market positioning. The adjustment, while modest, underscores the analyst’s view of Epiroc’s strong fundamentals and continued growth in…
- [Redefine Properties - Horse Group to remain jointly controlled by EPP GP, redefine Europe, and RMBIA](https://www.ainvest.com/news/redefine-properties-horse-group-remain-jointly-controlled-epp-gp-redefine-europe-rmbia-2610) — AInvest Wire, Oct 13, 2026
- [Maia Biotechnology achieves patient enrollment milestones in ongoing phase 2 and pivotal phase 3 clinical trials in non-small cell lung cancer](https://www.ainvest.com/news/maia-biotechnology-achieves-patient-enrollment-milestones-ongoing-phase-2-pivotal-phase-3-clinical-trials-small-cell-lung-cancer-2610) — AInvest Wire, Oct 7, 2026
  Maia Biotechnology has reached significant patient enrollment milestones in its ongoing phase 2 and pivotal phase 3 clinical trials for non-small cell lung cancer (NSCLC), according to recent updates. The company has activated multiple clinical trial sites and continues to expand access for…
- [Maia Biotechnology - Targets 100 patients dosed in Thio-104 by year-end 2026; interim analysis in 2027](https://www.ainvest.com/news/maia-biotechnology-targets-100-patients-dosed-thio-104-year-2026-interim-analysis-2027-2609) — AInvest Wire, Sep 23, 2026
  MAIA Biotechnology, Inc. (NYSE American: MAIA) has reported progress in its pivotal Phase 3 clinical trial, THIO-104, which is evaluating ateganosine as a third-line treatment for advanced non-small cell lung cancer (NSCLC). As of September 22, 2026, the company announced that 65 patients have been…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).